Gain critical insights into the dynamics of the oncology market to help drive your biosimilar strategy. In this white paper, we apply a synthesis of proprietary and public data to analyze the oncology market, applying lessons learned from the launch of Infliximab and more.
Our analysis discovered that health plans have adopted biosimilars of Trastuzumab as preferred products much sooner than was the case in the market of Infliximab and more. Download this white paper to learn more about oncology market drivers and behaviors.
We use our own and third parties cookies to improve your experience and our services. If you continue browsing, we take that to mean that you accept their uses and information.